INTRODUCTION: Poly (ADP-ribose) polymerase 1 (PARP-1) is the major target of clinical PARP inhibitors and is a potential predictive biomarker for response to therapy. Due to the limited success of PARP inhibitors as monotherapy, investigators have shifted the clinical role of PARP inhibitors to the adjuvant setting. In this study, we evaluate the radiotracer [18F]FluorThanatrace ([18F]FTT) as a marker of PARP expression in vitro and the associated biological implications of PARP-1 expression in PARP inhibitor treatment adjuvant to radiation therapy. MATERIALS AND METHODS: SNU-251 (BRCA1-mutant) and SKOV3 (BRCA1-WT) cell lines were evaluated in vitro by using the radiotracer [18F]FTT. Pharmacological binding assays were performed at baseline and were correlated with PARP-1 protein expression measured by Western blot protein analysis. Cell viability and clonogenic assays were used to characterize in vitro cytotoxicity for treatments, including: PARP inhibitors alone, radiation alone, and PARP inhibitor adjuvant to radiation. Western blot protein analysis was used to assess response to treatment by using γH2AX to measure DNA damage and PAR to measure the catalytic inhibition of PARP. RESULTS: [18F]FTT was capable of measuring PARP-1 protein expression in vitro and corresponded to Western blot protein analysis at baseline. The addition of a PARP inhibitor enhanced radiation effects in both cell lines; however, a greater synergy was observed in the SNU-251 cell line that expresses a BRCA1 mutation and homologous recombination deficiency. Western blot protein analysis showed that the addition of a PARP inhibitor adjuvant to radiation increases DNA damage in both cell lines and reduces PARP enzymatic activity as measured by PAR. CONCLUSIONS: In this work, we found that PARP-1 expression positively corresponds in vitro to the response of PARP inhibitors in combination with radiation therapy in ovarian cancer.
INTRODUCTION:Poly (ADP-ribose) polymerase 1 (PARP-1) is the major target of clinical PARP inhibitors and is a potential predictive biomarker for response to therapy. Due to the limited success of PARP inhibitors as monotherapy, investigators have shifted the clinical role of PARP inhibitors to the adjuvant setting. In this study, we evaluate the radiotracer [18F]FluorThanatrace ([18F]FTT) as a marker of PARP expression in vitro and the associated biological implications of PARP-1 expression in PARP inhibitor treatment adjuvant to radiation therapy. MATERIALS AND METHODS: SNU-251 (BRCA1-mutant) and SKOV3 (BRCA1-WT) cell lines were evaluated in vitro by using the radiotracer [18F]FTT. Pharmacological binding assays were performed at baseline and were correlated with PARP-1 protein expression measured by Western blot protein analysis. Cell viability and clonogenic assays were used to characterize in vitro cytotoxicity for treatments, including: PARP inhibitors alone, radiation alone, and PARP inhibitor adjuvant to radiation. Western blot protein analysis was used to assess response to treatment by using γH2AX to measure DNA damage and PAR to measure the catalytic inhibition of PARP. RESULTS: [18F]FTT was capable of measuring PARP-1 protein expression in vitro and corresponded to Western blot protein analysis at baseline. The addition of a PARP inhibitor enhanced radiation effects in both cell lines; however, a greater synergy was observed in the SNU-251 cell line that expresses a BRCA1 mutation and homologous recombination deficiency. Western blot protein analysis showed that the addition of a PARP inhibitor adjuvant to radiation increases DNA damage in both cell lines and reduces PARP enzymatic activity as measured by PAR. CONCLUSIONS: In this work, we found that PARP-1 expression positively corresponds in vitro to the response of PARP inhibitors in combination with radiation therapy in ovarian cancer.
Entities:
Keywords:
BRCA1; DNA damage; PARP inhibitor; PARP-1; ovarian cancer
Authors: Samuel F Bunting; Elsa Callén; Nancy Wong; Hua-Tang Chen; Federica Polato; Amanda Gunn; Anne Bothmer; Niklas Feldhahn; Oscar Fernandez-Capetillo; Liu Cao; Xiaoling Xu; Chu-Xia Deng; Toren Finkel; Michel Nussenzweig; Jeremy M Stark; André Nussenzweig Journal: Cell Date: 2010-04-01 Impact factor: 41.582
Authors: Christine E Edmonds; Mehran Makvandi; Brian P Lieberman; Kuiying Xu; Chenbo Zeng; Shihong Li; Catherine Hou; Hsiaoju Lee; Roger A Greenberg; David A Mankoff; Robert H Mach Journal: Am J Nucl Med Mol Imaging Date: 2016-01-28
Authors: Zhigang C Wang; Nicolai Juul Birkbak; Aedín C Culhane; Ronny Drapkin; Aquila Fatima; Ruiyang Tian; Matthew Schwede; Kathryn Alsop; Kathryn E Daniels; Huiying Piao; Joyce Liu; Dariush Etemadmoghadam; Alexander Miron; Helga B Salvesen; Gillian Mitchell; Anna DeFazio; John Quackenbush; Ross S Berkowitz; J Dirk Iglehart; David D L Bowtell; Ursula A Matulonis Journal: Clin Cancer Res Date: 2012-08-21 Impact factor: 12.531
Authors: Andrew R Green; Daniela Caracappa; Ahmed A Benhasouna; Alaa Alshareeda; Christopher C Nolan; R Douglas Macmillan; Srinivasan Madhusudan; Ian O Ellis; Emad A Rakha Journal: Breast Cancer Res Treat Date: 2014-12-21 Impact factor: 4.872
Authors: Kirsten M Timms; Victor Abkevich; Elisha Hughes; Chris Neff; Julia Reid; Brian Morris; Saritha Kalva; Jennifer Potter; Thanh V Tran; Jian Chen; Diana Iliev; Zaina Sangale; Eliso Tikishvili; Michael Perry; Andrey Zharkikh; Alexander Gutin; Jerry S Lanchbury Journal: Breast Cancer Res Date: 2014-12-05 Impact factor: 6.466
Authors: Mehran Makvandi; Kuiying Xu; Brian P Lieberman; Redmond-Craig Anderson; Samuel Sander Effron; Harrison D Winters; Chenbo Zeng; Elizabeth S McDonald; Daniel A Pryma; Roger A Greenberg; Robert H Mach Journal: Cancer Res Date: 2016-06-03 Impact factor: 13.312
Authors: Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier Journal: Cancer Res Date: 2012-11-01 Impact factor: 13.312
Authors: Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Med Res Rev Date: 2018-03-12 Impact factor: 12.944
Authors: Robert J Young; Paula Demétrio De Souza França; Giacomo Pirovano; Anna F Piotrowski; Philip J Nicklin; Christopher C Riedl; Jazmin Schwartz; Tejus A Bale; Patrick L Donabedian; Susanne Kossatz; Eva M Burnazi; Sheryl Roberts; Serge K Lyashchenko; Alexandra M Miller; Nelson S Moss; Megan Fiasconaro; Zhigang Zhang; Audrey Mauguen; Thomas Reiner; Mark P Dunphy Journal: Neurooncol Adv Date: 2020-09-15
Authors: Sophie Stotz; Johannes Kinzler; Anne T Nies; Matthias Schwab; Andreas Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2021-09-06 Impact factor: 9.236
Authors: Thomas C Wilson; Mary-Ann Xavier; James Knight; Stefan Verhoog; Julia Baguña Torres; Michael Mosley; Samantha L Hopkins; Sheena Wallington; Phillip D Allen; Veerle Kersemans; Rebekka Hueting; Sean Smart; Véronique Gouverneur; Bart Cornelissen Journal: J Nucl Med Date: 2018-11-02 Impact factor: 10.057